Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Bain Capital Life Sciences

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 63
Average round size
info
The average size of a deal this fund participated in
$114M
Portfolio companies 41
Rounds per year 10.50
Lead investments 11
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 22
Key employees 2
Stages of investment
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics
Summary

Bain Capital Life Sciences appeared to be the VC, which was created in 2016. The company was established in North America in United States. The leading representative office of defined VC is situated in the Boston.

The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Manufacturing, Health Care. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Annexon Biosciences, Rapid Micro Biosystems, Pharvaris

The overall number of key employees were 2.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Bain Capital Life Sciences, startups are often financed by Correlation Ventures, Omega Funds, Longitude Capital. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, Cormorant Asset Management, Foresite Capital. In the next rounds fund is usually obtained by Samsara BioCapital, Pfizer Venture Investments, Perceptive Advisors.

The increased amount of exits for fund were in 2018. Considering the real fund results, this VC is 70 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 50 - 100 millions dollars. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. This Bain Capital Life Sciences works on 21 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Bain Capital Life Sciences:
Typical Co-investors
Bain Capital Life Sciences is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Bain Capital Life Sciences:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

New Amsterdam Pharma

Biotechnology
Life Science
Pharmaceutical
$235M23 Nov 2022 The Netherlands, North Holland, Netherlands

Jnana

Biotechnology
Health Care
Therapeutics
$107M15 Nov 2022 Boston, Massachusetts, United States

Emalex Biosciences, Inc.

Biotechnology
Pharmaceutical
$250M03 Nov 2022 Illinois, United States

Solid Biosciences

Biotechnology
Genetics
Health Care
Medical
$75M30 Sep 2022 Marlborough, Massachusetts, United States

Rivus Pharmaceuticals

Biotechnology
Health Care
Medical
Pharmaceutical
$132M22 Sep 2022 Charlottesville, Virginia, United States

Nimbus Therapeutics

Alternative Medicine
Biotechnology
Health Care
Therapeutics
$125M12 Sep 2022 Cambridge, Massachusetts, United States

JenaValve Technology

Health Care
Medical
Medical Device
$100M31 Aug 2022 Munich, Bavaria, Germany

Areteia Therapeutics

Biotechnology
Health Care
Life Science
Therapeutics
$350M12 Jul 2022 -

Annexon Biosciences

Biotechnology
Health Care
Health Diagnostics
Life Science
Therapeutics
$130M08 Jul 2022 South San Francisco, California, United States
News
Amylyx Pharmaceuticals Raises $135M in Series C Financing

– Amylyx Pharmaceuticals, Inc. closed $135m in Series C financing.
Viking Global Investors led the round with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge.
– The company intends to use the funds for the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.

Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care

– Imperative Care, Inc. announced that it has closed a $260m Series D financing led by D1 Capital Partners.
– New investors HealthCor Investments LLC and Innovatus Capital Partners also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures participated in the financing.
– James Rogers from D1 will join Imperative Care’s Board of Directors.
– Proceeds from the financing will be used to support ongoing commercialization and development of a wide range of Imperative Care’s technologies in the broad continuum of stroke care, as well as to create a strategic network of wholly owned development subsidiaries in a number of areas of synergy.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Bain Capital Life Sciences?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: